Advances in clinical chemistry. Volume 50 / edited by Gregory S. Makowski.

Format:

• Book

Contributor:

• Makowski, Gregory.

Series:

• Advances in Clinical Chemistry
• Advances in clinical chemistry, 0065-2423

Language:

English

Subjects (All):

• Clinical chemistry.
• Clinical medicine.

Physical Description:

1 online resource (184 p.)

Place of Publication:

Amsterdam : Elsevier, 2010.

Language Note:

English

Summary:

Volume 47 in the internationally acclaimed Advances in Clinical Chemistry contains chapters submitted from leading experts from academia and clinical laboratory science. Authors are from a diverse field of clinical chemistry disciplines and diagnostics, ranging from basic biochemical exploration to cutting-edge microarray technology. Leading experts from academia and clinical laboratory science Volume emphasizes novel laboratory advances with application to clinical laboratory diagnostics and practical basic science studies.

Contents:

• Front Cover; Advances in Clinical Chemistry; Copyright Page; Contents; Contributors; Preface; Chapter 1: Biomarkers of Vulnerable Atheromatous Plaques: Translational Medicine Perspectives; 2. Background on Atherosclerosis and Vulnerable Plaques; 3. Concept of Biomarkers; 4. Imaging Biomarkers for Vulnerable Plaques; 4.1. Ultrasound; 4.2. Computed Tomography (CT); 4.3. Positron Emission Tomography (PET); 4.4. Magnetic Resonance Imaging (MRI); 4.5. Optical Imaging; 5. Circulating Biomarkers for Vulnerable Plaques; 5.1. Nonspecific Inflammatory Biomarkers; 5.2. Inflammatory Cytokines/Chemokines
• 5.3. Adhesion Molecules5.4. Matrix Metalloproteinases; 5.5. Other Inflammatory Markers; 5.6. Redox Biomarkers; 6. FDA Perspectives of Biomarkers; 7. Conclusion; References; Chapter 2: Haptoglobin Polymorphism and Infection; 2. Introduction; 3. Hp and CD163; 4. Hp Polymorphism and Infections; 4.1. Hp Polymorphism and Streptococcus pyogenes; 4.2. Hp Polymorphism and Neisseria meningitidis; 4.3. Hp Polymorphism and Vibrio vulnificus; 4.4. Hp Polymorphism and Haemophilus influenzae; 4.5. Hp Polymorphism and Tuberculosis; 4.6. Hp Polymorphism and Legionella pneumophila
• 4.7. Hp Polymorphism and Malaria4.8. Hp Polymorphism and Trypanosomiasis; 4.9. Hp Polymorphism and HIV; 4.10. Hp Polymorphism and EBV; 4.11. Hp Polymorphism and Hepatitis; 5. Hp and Vaccination; 6. Conclusion; Acknowledgment; References; Chapter 3: Serum Bilirubin Levels and Cardiovascular Disease Risk: A Janus Bifrons?; 2. Structure and Metabolism of Bilirubin; 3. Laboratory Measurement; 4. Hyperbilirubinemias; 5. Clinical Evidence; 6. Biological Evidences; 7. Conclusions; References; Chapter 4: NAD(P)H Oxidases in Coronary Artery Disease; 2. Introduction; 3. NAD(P)H Oxidases
• 4. Structure of NAD(P)H Oxidases5. NAD(P)H Oxidases in Coronary Artery Disease; 6. NAD(P)H Oxidases in Hypertension; 6.1. Angiotensin II-Related Hypertension; 6.2. NAD(P)H Oxidase-Derived Oxidative Stress in Hypertension; 6.3. NAD(P)H Oxidase and Endothelial Dysfunction in Hypertension; 6.4. NAD(P)H Oxidases in Experimental Hypertension Models; 7. NAD(P)H-Derived ROS as Second Messengers; 8. Effect of NADP(H)-Derived ROS on Gene Expression; 9. Effect of NAD(P)H Oxidases on Cell Growth; 10. Effect of NAD(P)H Oxidases on Apoptosis
• 11. NAD(P)H Oxidase and Plaque Formation in Coronary Artery DiseaseReferences; Chapter 5: Component-Resolved Allergy Diagnosis by Microarray: Potential, Pitfalls, and Prospects; 2. Introduction; 3. Historical Perspective; 4. Microarray: The Technique; 5. Clinical Experience with CRD Using Microarray; 6. Experience with the Microarray at the University of Antwerp; 7. Perspectives; 8. Conclusion; Acknowledgments; References; Chapter 6: Ocular Angiogenesis: Mechanisms and Recent Advances in Therapy; 2. Introduction; 3. Ocular Angiogenesis; 4. Angiogenic Factors Involved in Ocular Angiogenesis
• 4.1. VEGF

Notes:

• Description based upon print version of record.
• Includes bibliographical references and index.

ISBN:

• 1-282-77008-X
• 9786612770081
• 0-12-380984-3

OCLC:

700688820